AVEO Oncology Completes First Analysis of FIERCE-HN Study for Head and Neck Cancer Treatment AVEO Oncology announces the successful completion of the first interim analysis for the global FIERCE-HN study, focusing on a promising combination therapy for patients with advanced head and neck cancer.

AVEO Oncology Completes First Analysis of FIERCE-HN Study for Head and Neck Cancer Treatment #United_States #Boston #AVEO_Oncology #HNSCC #ficlatuzumab

AVEO Oncology Marks Milestone with First Patient Dosing in AML Study of Ficlatuzumab AVEO Oncology has announced the successful dosing of the first patient in a clinical trial for treating AML with ficlatuzumab, in partnership with Blood Cancer United.

AVEO Oncology Marks Milestone with First Patient Dosing in AML Study of Ficlatuzumab #USA #Boston #AVEO_Oncology #Blood_Cancer_United #ficlatuzumab